Berna Öksüzoğlu

Berna Öksüzoğlu

Auto-generated profile, based on publicly available information

Berna Öksüzoğlu

Dr. A. Y. Ankara Oncology Training and Research Hospital Department of Medical Oncology, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
BOBerna Oksüzoglu
Berna Oksüzoglu
HAHüseyin Abali
Hüseyin Abali
NGNilüfer Güler
Nilüfer Güler
EBEsmen Baltali
Esmen Baltali
YOYavuz Ozisik
Yavuz Ozisik

1 October 2005 in Hematology
Verified
Journal Article
Closed access
NYNuriye Yildirim
Nuriye Yildirim
BÖBerna Öksüzoğlu
Berna Öksüzoğlu
BBBurçin Budakoğlu
Burçin Budakoğlu
MVMurat Vural
Murat Vural
HAHüseyin Abali
Hüseyin Abali
NZNurullah Zengin
Nurullah Zengin
Primary gastrointestinal system lymphomas constitute about one third of all extranodal lymphomas. Duodenal involvement of the lymphoma is a rare condition. Periampullary lymphoma or lymphomatous involvement of ampulla of Vater is even rarer. Since, periampullary lymphoma is not easy to differentiate from epithelial carcinoma of these sites clinically and radiologically, accurate histopathological diagnosis is essential to plan optimal treatment strategy. Obstructive jaundice and the need for some form of drainage procedure and dose modification of the chemotherapy are additional challenges. In this report, we present three cases of duodenal diffuse large cell lymphoma with involvement of ampulla of Vater, two of whom presented with the initial signs of obstructive jaundice. One of the icteric patients was only diagnosed histopathologically following an explorative laparotomy with the initial diagnosis of carcinoma.

1 December 2002 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
BÖBerna Öksüzoğlu
Berna Öksüzoğlu
SKSaadettin Kiliçkap
Saadettin Kiliçkap
ŞYŞuayib Yalcin
Şuayib Yalcin
Impairment of liver function can be seen in cancer patients for a variety of reasons including metastasis, biliary obstruction, toxicity of chemotherapy or other concomittant drugs, can be paraneoplastic or can be due to infections, especially with hepatotropic viruses. Mostly reported in hematological malignancies, reactivation of hepatitis B virus (HBV) is a complication of chronic HBV infection in patients under cytotoxic or immunosuppressive therapy. Up to now, only a few cases of hepatitis B reactivation have been described in patients with solid tumors. We report an acute reversible deterioration of liver function tests following cytotoxic chemotherapy in an HBsAg-positive patient with metastatic pancreatic cancer due to hepatitis B reactivation. As far as we know, this is the first case of pancreatic carcinoma with reactivation following chemotherapy. As experience with acute flares of HBV carriers in solid tumors increases, the establishment of guidelines for the management of these patients has become more crucial.

1 June 2005 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
NYNuriye Yıldırım
Nuriye Yıldırım
BÖBerna Öksüzoğlu
Berna Öksüzoğlu
MVMurat Vural
Murat Vural
ÖHÖzge Han
Özge Han
NZNurullah Zengin
Nurullah Zengin

24 May 2007 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
MPMerve Pamukcuoglu
Merve Pamukcuoglu
BBBurçin Budakoğlu
Burçin Budakoğlu
ÖHÖzge Han
Özge Han
MTMurat Tad
Murat Tad
BÖBerna Öksüzoğlu
Berna Öksüzoğlu
NZNurullah Zengin
Nurullah Zengin

1 February 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HAHuseyin Abali
Huseyin Abali
SYSuayib Yalcin
Suayib Yalcin
HOHuseyin Cem Onal
Huseyin Cem Onal
FDFaysal Dane
Faysal Dane
BOBerna Oksuzoglu
Berna Oksuzoglu
ACArzu Calisgan
Arzu Calisgan
TPS182 Background: Trastuzumab in combination with chemotherapy has been shown to prolong survival of HER2+ esophago-gastric cancer patients. The primary aim of our study was to evaluate safety and tolerability of trastuzumab (T) in combination with oxaliplatine (O), capecitabine (C) and radiation (R) therapy in the adjuvant setting in curatively resected esophago-gastric cancer patients. Methods: Forty patients with IB or higher stages was planned to be recruited and here we report the interim analyses on 22. We would consider the study positive if at least 64.4% of patients could tolerate the therapy. Eligible patients received T 8 mg/kg intravenously (iv) on Day 1 of cycle 1 and 6 mg/kg iv on day 1 of every following 3-weekly cycle for 1 year as 17 cycles, with O 100 mg/m2 iv on Day 1 of cycles 1-3 and C 850 mg/m2 orally twice daily on days 1-14 of cycles 1-3 and on 5 days per week during chemo-radiotherapy. R was given at a total dose of 45 Gy divided into 25 doses on 5 treatment days per week for 5 weeks starting from the 1st day of cycle 4. Results The median age was 57.5 years (Min-Max: 35-74). Of 22 patients; 15 were male (68.2%), 21 (95.5%) had an ECOG PS score ≤ 1, 21 (95.5%) had D2 lymph node resection. There were 11 serious adverse events. Two patients died on therapy; 1 secondary to pulmonary thrombo-emboli, and the other had to cerebral ischemia (thought to be due to Behçet’s disease), and 7 died of progression. There were 6 dose reductions (1 for T, 2 for O and 3 for C), T was stopped in 1 patient, C was interrupted 8 times (mostly during radiotherapy). Patients who have completed 3 cycles of O, C, T and 4th and 5th cycles of chemo-radiation therapy with C and T were defined as tolerable. Out of 22 patients, 19 (86.4%) were tolerable (Chi Square test: p = 0.0623). Median survival time for interim analysis patients (n = 22) was 22 months (95% CI: 11-23 months). Conclusion T in combination with O, C and chemo-radiation with C and T was tolerable with the tolerability rate of 86.4%, in curatively resected HER2 + esophago-gastric cancer adjuvant treatment. Clinical trial information: NCT01748773.